NDLI: Developing good scientific publishing practices: one pharmaceutical company's perspective.

Please wait, while we are loading the content...

Year: 2017 Volume: 33

Year: 2016 Volume: 32

Year: 2015 Volume: 31

Year: 2014 Volume: 30

Year: 2013 Volume: 29

Year: 2012 Volume: 28

Year: 2011 Volume: 27

Year: 2010 Volume: 26

Year: 2010 Volume: 26 Issue: 12

Year: 2010 Volume: 26 Issue: 11

Year: 2010 Volume: 26 Issue: 10

Year: 2010 Volume: 26 Issue: 9

Year: 2010 Volume: 26 Issue: 8

Year: 2010 Volume: 26 Issue: 7

Year: 2010 Volume: 26 Issue: 6

Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.

Study of levocetirizine in seasonal allergic rhinitis.

Developing good scientific publishing practices: one pharmaceutical company's perspective.

Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.

Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.

Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy.

Prescription patterns of antidepressants: findings from a US claims database.

Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.

Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.

The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.

Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.

Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.

Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China.

Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.

Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis.

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.

Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.

Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2.

Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes.

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations.

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.

Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.

Year: 2010 Volume: 26 Issue: 5

Year: 2010 Volume: 26 Issue: 4

Year: 2010 Volume: 26 Issue: 3

Year: 2010 Volume: 26 Issue: Supplementary 3

Year: 2010 Volume: 26 Issue: 2

Year: 2010 Volume: 26 Issue: Supplementary 2

Year: 2010 Volume: 26 Issue: 1

Year: 2010 Volume: 26 Issue: Supplementary 1

Year: 2009 Volume: 25

Year: 2008 Volume: 24

Year: 2007 Volume: 23

Year: 2006 Volume: 22

Year: 1983 Volume: 8

Developing good scientific publishing practices: one pharmaceutical company's perspective.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Dowsett, Sherie A. Van Campen, Luann E. Bednar, Lisa A.
Description	Country affiliation: United States Author Affiliation: Dowsett SA ( Eli Lilly and Company, Indianapolis, IN 46285, USA. Dowsettsa@lilly.com)
Abstract	BACKGROUND: The scientific publishing practices of the pharmaceutical industry have been heavily criticized in recent years due to the inherent conflict of interest that arises when a pharmaceutical company publishes findings around its own drugs. SCOPE: Eli Lilly and Company ('Lilly') strives for transparency in its day-to-day activities, and, here, shares its principles, policies and practices on publishing 'Lilly-sponsored' research. FINDINGS: A conflict of interest does not necessarily equate to biased presentation of research findings, and operating a successful, for-profit business and maintaining a focus on improving the health of patients are not mutually exclusive goals. There is, however, potential for bias, and it is incumbent upon a for-profit to develop publication principles, policies and practices to address this. To this end, Lilly's Principles of Medical Research states that 'Lilly discloses publicly all medical research results that are important to patients, healthcare providers or payers--whether favorable or unfavorable to a Lilly product--in an accurate, objective, and balanced manner ...' The preparation of publications of Lilly-sponsored research involves close collaboration between external (i.e., academic or otherwise non-industry employees) and Lilly scientific researchers (including scientific writers), with both serving as authors. Lilly does not support 'ghost' or 'guest' authorship. Authorship is not just recognition of contribution but also public acknowledgement of responsibility for content, and all authors are expected to take an active role in developing the manuscript in line with the International Committee of Medical Journal Editors-based authorship requirements. This is agreed to by authors before the manuscript is started. Lilly provides external authors with access to the trial data for manuscript development. Lilly does not pay external authors for their involvement in manuscript development. Scientific writers at Lilly, often with advanced scientific degrees, offer both scientific and writing expertise in manuscript development and play a project management role. Their role is transparent, and they are included as authors or appropriately acknowledged. CONCLUSION: Lilly has an ongoing commitment to appropriate publishing practices. Sharing company publication principles, policies and practices is one way to demonstrate this commitment and encourage and facilitate open dialogue among all those involved in drug development.
File Format	HTM / HTML
ISSN	03007995
Issue Number	6
Volume Number	26
e-ISSN	14734877
Journal	Current Medical Research and Opinion
Language	English
Publisher	Taylor & Francis
Publisher Date	2010-06-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Medicine Biomedical Research Drug Industry Editorial Policies Authorship Conflict Of Interest Journalism Publication Bias Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Medicine

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in